CHADS Score, Statin Therapy, and Risks of Atrial Fibrillation
Authors:
- Ching-Heng LinCLChing-Heng Lin
- El-Wui LohELEl-Wui Loh
- Chih-Tai TingCTChih-Tai Ting
- Tsu-Juey WuTWTsu-Juey Wu
- 1 February 2013
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 126 (2) , 133-140.e1
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trialEuropean Heart Journal, 2011
- Associations among the CHADS2 score, atrial substrate properties, and outcome of catheter ablation in patients with paroxysmal atrial fibrillationHeart Rhythm, 2011
- Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary preventionEP Europace, 2011
- The incidence and risk factors for new onset atrial fibrillation in the PROSPER studyEP Europace, 2011
- Upstream Effect for Atrial Fibrillation: Still a Dilemma?Pacing and Clinical Electrophysiology, 2010
- Usefulness of CHADS2 Score to Predict C-Reactive Protein, Left Atrial Blood Stasis, and Prognosis in Patients With Nonrheumatic Atrial FibrillationThe American Journal of Cardiology, 2010
- Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)JACC, 2009
- Atrial Fibrillation and CHADS2 Risk Factors are Associated with Highly Sensitive C‐Reactive Protein Incrementally and IndependentlyPacing and Clinical Electrophysiology, 2009
- Selecting Patients With Atrial Fibrillation for AnticoagulationCirculation, 2004
- Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available.The American Journal of Cardiology, 1998